BioSpace News Archive

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SLS009, a novel and highly selective CDK9 inhibitor, for the treatment of acute myeloid leukemia (AML).

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its Analyst & Investor Day event scheduled for Friday, October 13, 2023.

Researchers from Invitae, a leading medical genetics company, are showcasing their work next week at the National Society of Genetic Counselors 42nd Annual Conference in Chicago that highlights the importance of genetics-informed patient care.

Mural Oncology plc, the publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS) plans to establish in the fourth quarter of 2023 (Mural Oncology), will hold an investor webcast during which members of Mural Oncology’s designated management team will provide an overview of the company, its pipeline and strategy.

Evolent Health, Inc. (NYSE: EVH) today announced it will release its third quarter 2023 financial results on Thursday, Nov. 2, 2023, after market close, with a conference call to follow at 5 p.m. ET.

MediciNova, Inc. today announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS).

Astellas Pharma Inc. and BioLabs Global, Inc. and Mitsui Fudosan announced that they have agreed on a tri-party memorandum of understanding to enhance the life science ecosystem in Tsukuba and Kashiwa-no-ha, Japan, world-renowned science hubs.

Ascletis Pharma Inc. (HKEX:1672, “Ascletis”) today announces the poster presentation of Phase II study topline results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany.

Gritgen Therapeutics Co., Ltd., a biotechnology company focused on discovering and developing innovative gene therapy products, announces the successful validation and official launching of operations at its commercial GMP facility located in Suzhou Industrial Park.

TaiGen Biopharmaceuticals Holdings Ltd. announces that TaiGen Biotechnology, a subsidiary company of TaiGen, have signed an exclusive licensing agreement with Y.S.P. Industries Sdn. Bhd. to develop and commercialize TaiGen’s new drug in Malaysia and Singapore.